Corticosteroids in the prevention and management of bronchopulmonary dysplasia

Seminars in Neonatology

Volumn 8, Issue 1, 2003, Pages 83-91

  Grier, David G ^a,b   Halliday, Henry L ^a,b  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Corticosteroids; Glucocorticoids; Neonate; Preterm; Review

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; METHYLPREDNISOLONE; STRONTIUM SULFATE;

ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; CEREBRAL PALSY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG STRUCTURE; EVIDENCE BASED MEDICINE; EXTUBATION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FUNCTION; MYELIN DEFICIENCY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NEWBORN INTENSIVE CARE; NONHUMAN; OUTCOMES RESEARCH; PERINATAL PERIOD; PREMATURITY; REVIEW; STRUCTURE ANALYSIS;

EID: 0037299033     PISSN: 10842756     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1084-2756(02)00189-6     Document Type: Review

References (62)

1. Sweet DG, Halliday HL. A risk-benefit assessment of drugs used for neonatal chronic lung disease. Drug Saf 2000;22:389-404.
2. Haddad HM, Hsia DYY, Gellis SS. Studies on respiratory rate in the newborn; its use in the evaluation of respiratory distress in infants of diabetic mothers. Pediatrics 1956;86:204-13.
3. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-72.
4. Groneck P, Reuss D, Gotze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 1993;122:938-44.
5. Gerdes JS, Harris MC, Polin RA. Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates. J Pediatr 1988;113:727-31.
6. Vyas J, Kotecha S. Effects of antenatal and postnatal corticosteroids on the preterm lung. Arch Dis Child Fetal Neonatal Ed 1997;77:F147-50.
7. Bolt RJ, van Weissenbruch MM, Lafeber HN, Delemarre-van de Waal HA. Glucocorticoids and lung development in the fetus and preterm infant. Pediatr Pulmonol 2001;32:76-91.
8. Bunton TE, Plopper CG. Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque. Am J Obstet Gynecol 1984;148:203-15.
9. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. Biol Neonate 1995;68:229-45.
10. Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest 1985;76:1297-305.
11. Liggins GC. Premature parturition after infusion of corticotrophin or cortisol into foetal lambs. J Endocrinol 1968;42:323-9.
12. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.
13. Ballard PL, Ning Y, Polk D, Ikegami M, Jobe AH. Glucocorticoid regulation of surfactant components in immature lambs. Am J Physiol 1997;273:L1048-57.
14. Xu ZX, Viviano CJ, Rooney SA. Glucocorticoid stimulation of fatty-acid synthase gene transcription in fetal lung: antagonism by retinoic acid. Am J Physiol 1995;268:L683-90.
15. Rooney SA. Regulation of surfactant phospholipid biosynthesis. In: Rooney SA, editor. Lung surfactant: cellular and molecular processing. Austin, TX: RG Landes 1998;29-45.
16. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972;50:526-34.
17. Taeusch HW, Wang NS, Baden N, Bauer CR, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. II. Pathology. Pediatrics 1973;52:850-4.
18. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53:877-83.
19. Ewerbeck H, Helwig H, Reynolds JW, Provenzano RW. Treatment of idiopathic respiratory distress with large doses of corticoids. Pediatrics 1972;49:467-8.
20. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;8338:1356-8.
21. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985;75:106-11.
22. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 1999;53:193-218.
23. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101:E7 http://www.pediatrics.org/cgi/content/full/101/5/e7.
24. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants (Cochrane Review). The Cochrane Library. Oxford: Update Software 2001;Issue 3.
25. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Cochrane Review). The Cochrane Library. Oxford: Update Software 2001;Issue 3.
26. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants (Cochrane Review). The Cochrane Library. Oxford: Update Software 2001;Issue 3.
27. Barrington JK. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001;1:1 http://www.biomedcentral.com/1471-2431/1/1.
28. Halliday HL. Postnatal steroids: a dilemma for the neonatologist. Acta Paediatr 2001;90:116-8.
29. Ramanathan R, Siassi B, Sardesai S, DeLemos R. Comparison of two dosage regimens of dexamethasone for early treatment of chronic lung disease in very low birth weight (VLBW) infants: a double-blinded, randomised trial. Pediatr Res 1996;37:229A.
30. Durand M, Mendoza ME, Tantivit P, Kugelman A, McEvoy C. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002;109:262-8.
31. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001;344:95-101.
32. Cole HC, Franz ID. Role of postnatal steroids for chronic lung disease. In: Hanson TN, McIntosh N, editors. Current topics in neonatology. London: WB Saunders 1997;vol. 2:256-80.
33. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989;320:1505-10.
34. Bloomfield FH, Knight DB, Harding JE. Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. J Pediatr 1998;133:395-400.
35. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med 1998;338:1112-8.
36. Howard H. Reductions in size and total DNA of cerebellum in adult mice after corticosteroid treatment in infancy. Exp Neural 1968;22:191-208.
37. Uno H, Lohmiller L, Thieme C, Kemnitz JW, Engle MJ, Roecker EB et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Dev Brain Res 1990;53:157-67.
38. Huang WL, Beazley LD, Quinlivan JA, Evans SF, Newnham JP, Dunlop SA. Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol 1999;94:213-8.
39. Flagel SB, Vazquez DM, Watson SJ Jr., Neal CR Jr. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol Regul Integr Comp Physiol 2002;282:R55-63.
40. McEwen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann N Y Acad Sci 1997;821:271-84.
41. Whitelaw A, Thoresen M. Antenatal steroids and the developing brain. Arch Dis Child Fetal Neonatal Ed 2000;83:F154-7.
42. Edwards HE, Burnham WM. The impact of corticosteroids on the developing animal. Pediatr Res 2001;50:433-40.
43. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001;107:217-21.
44. Riva MA, Fumagalli F, Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone treatment. J Neurochem 1995;64:2526-33.
45. Quinlivan JA, Archer MA, Evans SF, Newnham JP, Dunlop SA. Fetal sciatic nerve growth is delayed following repeated maternal injections of corticosteroid in sheep. J Perinat Med 2000;28:26-33.
46. Tsubota S, Adachi N, Chen J, Yorozuya T, Nagaro T, Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology 1999;90:515-23.
47. Matthews SG. Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res 2000;47:291-300.
48. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol 2001;86(Suppl):23-5.
49. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999;341:1190-6.
50. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001;50:706-11.
51. Tuor UI, Yager JY, Bascaramurty S, Del Bigio MR. Dexamethasone prevents hypoxia/ischemia-induced reductions in cerebral glucose utilization and high-energy phosphate metabolites in immature brain. J Neurochem 1997;69:1954-63.
52. Andre P, Thebaud B, Odievre MH, Razafimahefa H, Zupan V, Dehan M et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000;26:1496-500.
53. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258-63.
54. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res 2001;50:190-5.
55. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates (Cochrane Review). The Cochrane Library. Oxford: Update Software 2001;Issue 3.
56. Halliday HL, Patterson CC, Halahakoon CW. A multicenter randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 2001;107:232-4.
57. American Academy of Pediatrics Committee on Fetus and Newborn, Canadian Paediatric Society Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-8.
58. Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics 2001;108:741-8.
59. Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health 2000;36:101-7.
60. Halliday HL. Perinatal corticosteroid treatment-helpful or harmful. Arch Perinat Med 2000;6:7-9.
61. Halliday HL. Guidelines on neonatal steroids. Prenat Neonatal Med 2001;6:371-3.
62. Halliday HL. Early postnatal dexamethasone and cerebral palsy. Pediatrics 2002;109:1168-9.